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Summary
Foxp3+ regulatory T cells (Tregs) maintain immune tol-
erance, prevent autoimmunity and modulate immune re-
sponses during infection and cancer. Recent studies have
revealed considerable heterogeneity and plasticity within
the Treg compartment, depending on the immunological
context, which may result in Tregs losing their suppressive
function in inflammatory environments. We review how
dysfunctional Tregs contribute to disease pathogenesis in
inflammatory conditions and how inappropriate regulatory
responses may hamper protective immunity in the context
of infection and cancer. We also discuss how Tregs might
be targeted therapeutically to re-establish a proper balance
between regulatory and effector responses in autoimmu-
nity, infections, and cancer.
Key words: regulatory T cells; autoimmunity; infections;
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Introduction
Regulatory T cells (Tregs) are a subset of CD4+ T cells
that are crucial for immune homeostasis. Tregs are defined
by their expression of the transcription factor forkhead-box
protein P3 (Foxp3), which is essential for their develop-
ment and suppressive function [1]. Loss of Foxp3 function
leads to severe lymphoproliferative disease and autoimmu-
nity, and highlights the essential role of Tregs in main-
taining immune tolerance [2, 3]. In addition to preventing
autoimmunity and inflammatory diseases, Tregs ensure a
controlled immune response upon pathogen encounter and
thereby prevent immune pathology. Conversely, excessive
suppression by Tregs can hamper pathogen clearance and
promote chronic infection [4, 5]. In addition, Tregs can
also restrain anti-tumour immune responses and thus pro-
mote tumour progression [6]. Properly balanced Treg func-
tion and activation is therefore essential to prevent im-
mune pathology but allow for protective immune responses
against tumours and pathogens.
To accomplish these tasks, Tregs must adapt to their im-
mune environment and specialise into subsets with distinct
functional properties that work together to ensure an ad-
equate immune response while maintaining immune toler-
ance [7]. However, the plasticity required for this special-
isation also bears the risk of instability, and recent studies
have revealed the ability of Tregs to loose suppressive
and acquire effector function [8, 9]. These observations re-
veal a potential causative role of unstable or dysfunctional
Tregs in inflammatory settings. Therefore, understanding
the factors that control Treg stability, plasticity and func-
tion is an important step towards improving safety and ef-
ficacy of therapeutic applications directed against Tregs.
In this review, we discuss the role of Tregs in autoimmu-
nity, infectious diseases, and cancer by addressing: the im-
portance of a fine-tuned regulatory response for maintain-
ing a healthy balance between effector and regulatory T
cell responses; Treg specialisation and heterogeneity and
its impact on Treg function and stability in inflammatory
settings; therapeutic approaches used to manipulate Treg
numbers and function.
Regulatory T cells in autoimmunity
The importance of Tregs in preventing autoimmunity be-
comes evident in patients with IPEX (immunodysregula-
tion polyendocrinopathy enteropathy X-linked syndrome),
who suffer from multi-organ autoimmunity because of a
mutation in the FOXP3 gene and hence impaired Treg
function [2, 3]. In addition, perturbations in the pathways
of the Treg suppressive network, including the interleukin
(IL)-2 / IL-2 receptor α-chain (IL-2Rα, CD25) axis or the
co-inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte-
associated protein 4), predispose to autoimmune disorders
[10, 11]. Whereas it is generally accepted that Tregs are
essential for maintaining self-tolerance, studies addressing
whether altered Treg frequencies and/or function affect the
disease course or severity of e.g. type 1 diabetes [12],
systemic lupus erythematosus [13], or rheumatoid arthritis
[14] have led to largely confounding findings. However,
differences in the markers used to define the Treg popula-
tion and hence the purity and composition of the analysed
Treg population might in part account for the divergent
findings, and highlight the importance of a standardised set
of markers that allows for cross-comparison between in-
dependent studies (table 1). Nowadays a general consensus
exists that in humans FoxP3-expressing Tregs are most ac-
curately defined as CD4+CD25+CD127- cells [15, 16].
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The role of Tregs defined on the basis of these markers
has been studied most extensively in multiple sclerosis.
Multiple sclerosis patients with relapsing-remitting disease
have reduced frequencies of Tregs with impaired suppress-
ive capacity [17, 18]. Decreased expression levels of
FoxP3 [17] as well as of CTLA-4 [19] detected in multiple
sclerosis patients were attributed to Treg dysfunction. Im-
portantly, treatment of multiple sclerosis with interferon-
beta (IFN-β) [17] and glatiramer acetate [20] restores Treg
numbers and FoxP3 expression levels, supporting a pro-
tective role of Tregs in multiple sclerosis.
Within their reduced Treg pool, patients with multiple
sclerosis show an accumulation ofTh1-like Tregs that pro-
duce interferon-gamma (IFN-γ) [21] (Th1: type 1 T helper
cell; table 2). The production of IFN-γ in these Tregs was
accompanied by upregulation of the Th1 master transcrip-
tion factor T-bet and loss of suppressive function. Blockade
of IFN-γ could re-establish the suppressive capacity of the
Tregs while the initial induction of the Th1-like pheno-
type was dependent on IL-12 signalling. Importantly, IFN-
β treatment reduced frequencies of IFN-γ-producing
Figure 1
Therapeutic targeting of the effector T cell–Treg balance.
Depicted are approaches that can restore a dysfunctional ratio of
effector T cells and Tregs in different diseases to the healthy state
(A). (B) In autoimmune diseases, self-tolerance is lost and
autoreactive effector T cells expand. In Th17-driven autoimmune
diseases, blocking of IL-6 signalling favours Treg and inhibits Th17
differentiation. Low-dose IL-2 therapy, which leads to expansion of
Tregs and thus restores a healthy effector T cell–Treg balance
represents a more general approach for treatment of autoimmunity.
(C) Application of high-dose IL-2 results in expansion of effector T
cells and induction of antitumor immune responses in cancer
patients. Checkpoint inhibitors block signalling through inhibitory
receptors such as PD-1 or CTLA-4 and can thus reverse T cell
exhaustion, which favours immune evasion of tumour cells or
pathogens. Blockade of these pathways can additionally support
the function of effector T cells by reducing the suppressive capacity
of Tregs.
CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; IL =
interleukin; PD-1 = programmed death 1; Th = T helper cell; Treg =
regulatory T cell
Th1-Tregs in multiple sclerosis patients to normal levels
[21]. Similar findings were reported in patients with type 1
diabetes [22], supporting a protective role of Tregs in the
disease.
Mouse models in which Tregs lack the ability to co-express
Foxp3 together with effector Th lineage-specific transcrip-
tion factors revealed the ability of Tregs to specialise dur-
ing the course of inflammatory responses. Driven by the
corresponding cytokine environment, co-expression of T-
bet or Stat3 was shown to be indispensable for control of
Th1 or Th17 effector T cell responses, respectively [23,
24]. In the mouse model, delayed induction of the
IL-12Rβ2 chain prevented Th1-specialised Tregs from
fully differentiating into potentially pathogenic IFN-γ-pro-
ducing Tregs [25]. The appearance of IFN-γ-producing
Tregs in patients with multiple sclerosis suggests that this
pathway is defective in these patients. A recent study repor-
ted the accumulation of Tregs expressing T-bet in the cent-
ral nervous system of mice during experimental autoim-
mune encephalomyelitis, the mouse model of multiple
sclerosis. However, in contrast to the initial reports, T-bet
deficiency in Tregs had no impact on the control of the
proinflammatory T cell response in this study [26]. These
findings indicate that specialisation might not be univer-
sally required for Treg function and homing. It will thus be
important to evaluate whether Treg specialisation is bene-
ficial or potentially harmful in different inflammatory dis-
eases.
In patients with rheumatoid arthritis, Tregs are counterin-
tuitively enriched in the synovial fluid, the site of inflam-
mation [27, 28], raising the question of whether they are
dysfunctional and thus unable to prevent disease. When ex-
amined for their functional properties, Tregs isolated from
the synovial fluid of patients with rheumatoid arthritis re-
tained their ability to suppress effector T cell proliferation
in vitro [27, 28], but displayed defects in suppression of ef-
fector cytokine production (table 2) [14]. Furthermore, the
inflammatory environment in rheumatoid arthritis, partic-
ularly the presence of tumour necrosis factor-alpha (TNF-
α), led to a loss in the suppressive function of Tregs [14,
29]. Whether this is also the case in other autoimmune set-
tings is still unclear [30]. Parallel to the IFN-γ-producing
Th1-Tregs observed in multiple sclerosis, Tregs from
rheumatoid arthritis patients have the potential to secrete
the proinflammatory cytokine IL-17 when re-stimulated
ex vivo [31]. However, in contrast to IFN-γ-producing
Th1-Tregs, they retain their ability to suppress effector
cell proliferation in vitro [32, 33]. IL-17-secreting FoxP3+
Tregs were first described under steady-state conditions,
and co-express FoxP3 and the Th17 master transcription
factor RORγt (retinoic acid receptor-related orphan recept-
or gamma-t) [32–34]. Despite the fact that they retain their
suppressive capacity, FoxP3+RORγt+ Tregs secrete IL-17
in response to IL-1β or IL-6 and thereby potentially con-
tribute to inflammation [32, 33]. The relevance of these
Th17-like Treg cells in autoimmune inflammation still re-
mains unclear, but again highlights the importance of con-
sidering Treg heterogeneity and subset distribution in dis-
ease settings.
The pathological importance of Treg plasticity and the abil-
ity of Tregs to adapt effector function under inflammatory
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conditions were investigated in the mouse model of
collagen-induced arthritis. Exposure of CD25lowFoxp3+ T
cells to high levels of IL-6, as encountered during arthritis,
resulted in a loss of Foxp3 expression in this still plastic
population and thus converted them into IL-17-secreting T
cells driving pathology [35]. This highlights the importance
of Treg stability when addressing the imbalance between
effector T cells and Tregs in inflammatory diseases. A
number of studies have focused on the question of whether
Tregs are stable or if they can convert into other potentially
pathogenic T cell phenotypes. In addition to sustained ex-
pression of Foxp3 and CD25, the unique epigenetic signa-
ture of Tregs, marked by hypomethylation of CpG motifs
in key genes such as the Foxp3 conserved noncoding se-
quence 2 (CNS2), Il2ra (CD25), Ikzf4 (Eos) and Ctla4, en-
sures Treg stability and maintenance of a functional Treg
phenotype [36–38]. The epigenetic programming of Tregs
may even ensure their long-term stability when Foxp3 ex-
pression is transiently lost [39, 40]. However, this topic
is still somewhat controversial and some studies suggest
that Tregs can permanently lose Foxp3 expression under
inflammatory conditions and convert to “ex-Tregs” exhib-
iting a pathogenic phenotype [41, 42]. Whether these “ex-
Tregs” actually underwent epigenetic reprogramming or
rather represent precursors that only transiently upregu-
lated Foxp3 is also not entirely clear. Regardless of this de-
bate, a better understanding of Treg stability is a prerequis-
ite for the development of Treg cell therapy, especially for
treatment in inflammatory settings.
On the basis of these observations it is clear that in both
Th1- and Th17-dominated autoimmune settings, Treg num-
bers as well as their function are critical determinants for
disease progression. Therapeutic approaches should thus
aim at restoring a healthy balance between effector cells
and functional Tregs (fig. 1B). Th17 and Treg cells share
the dependence on transforming growth factor-beta (TGF-
β) for their development, but the presence of IL-6 drives
their differentiation towards the Th17 lineage [43–45]. In-
terference with the IL-6-derived signal, for example with a
blocking antibody to the IL-6 receptor (tocilizumab), thus
inhibits Th17 but supports Treg differentiation. This thera-
peutic approach has successfully been used in rheumatoid
arthritis, where treatment resulted in an increase in Treg but
not Th17 numbers, restoring the Treg/Th17 balance [46].
Ongoing studies on IL-2 treatment, as key cytokine in Treg
development and maintenance, have demonstrated a spe-
cific activation and expansion of Tregs, but not effector T
cells, when low doses of IL-2 are administered, suggest-
ing a more general approach for modulation of the T ef-
fector / Treg balance to treat autoimmune diseases [47].
Similarly, adoptive immunotherapy with ex-vivo expanded
CD4+CD25+CD127- polyclonal Tregs is another interest-
ing approach to restoring the T effector / Treg balance in
multiple autoimmune diseases [48]. However, many open
issues regarding the stability and functionality of Tregs
expanded in vitro still need to be addressed before this ap-
proach could become broadly applicable.
In summary, Tregs are a very heterogeneous population
harbouring subsets with a high level of plasticity and pos-
sibly variable thresholds for stability under inflammatory
conditions. The assessment of Tregs defined by their stabil-
ity and suppressive properties in the relevant inflammatory
setting of each autoimmune disease will be key in ensuring
the efficacy of re-establishing the T effector / Treg balance
through therapeutic approaches.
Regulatory T cells in infectious
diseases
Pathogens and nascent transformed cells that can progress
to cancer pose a constant threat to the host, which must
be kept in check through appropriate immune responses.
However, excessive responses resulting from failure to ad-
equately control the magnitude and extent of the response
can result in collateral damage of affected tissues and or-
gans, also known as immunopathology [49]. A number of
Table 1: Marker combinations to identify regulatory T cells (Tregs).
Marker combination Represented
population
Organism Comments References
CD4+CD25+ Tregs and activated
effector T cells
Mouse/
human
Activated effector T cells upregulate CD25.
Tregs Mouse Exclusive marker combination to identify Tregs.CD4+CD25highFoxP3+
Tregs and activated
effector T cells
Human Activated effector T cells transiently upregulate FoxP3.
CD4+CD25highCD127– Primarily Tregs Human Most accurate marker combination to identify FoxP3+ Treg cells. Combination widely-used
for Treg isolation when cell permeabilisation for FoxP3 detection is not possible (e.g., for
functional assays).
[15, 16, 48]
Table 2: Subsets of human regulatory T cells (Tregs) and their potential role in autoimmune disease.
Markers Function
FoxP3 CD25 Other markers Suppression Effector cytokines Comments
References
+ ++ CD45RA+CTLA-4low +++ – Resting or naive Tregs
+++ +++ CD45RA–CTLA-4high +++ – Effector or activated Tregs
+ ++ CD45RA–CTLA-4int – IL-2, IFN-γ Treg precursor, may lose FoxP3 expression
+++ +++ CD45RA–CCR6+
CD45RA–HLA-DR–CCR6+
CD45RA–CD27+CCR6+
+++ IL-17 (express RORγt) [32–34]
+++ +++ CD45RA–CD127– + IFN-γ (express T-bet, CXCR3) Subset increased in MS and T1D patients. [21, 22]
CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; CXCR3 = C-X-C motif chemokine receptor type 3; FoxP3 = forkhead-box protein P3; IFN = interferon; IL =
interleukin; MS = multiple sclerosis; RORγt = retinoic acid receptor-related orphan receptor gamma-t; T1D = type 1 diabetes
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studies have shown that Tregs can help to minimise such
immune-mediated tissue damage. These focused on infec-
tious settings that can result in immunopathology under
certain conditions. As of now, only a limited number of
studies have addressed the tissue protective role of Tregs
in infections in humans. However, observations made in
infectious mouse models provide valuable insight on the
mechanisms contributing to immune pathology and outline
potential therapeutic approaches targeting Tregs in hu-
mans.
Persistent herpes simplex virus infection can result in a
form of keratitis in the human eye, in which excessive T
cell responses cause lesions in the cornea ultimately lead-
ing to blindness. In the mouse model, Tregs were able to re-
duce the severity of viral inflammatory lesions by dampen-
ing the Th1 response and influx of CD4+ effector T cells
into the cornea, demonstrating the tissue protective role of
Tregs in this setting [50]. Similarly, in Helicobacter hep-
aticus infection, a model of microbe-associated gut inflam-
mation, adoptively transferred Tregs were also able to in-
hibit T cell-mediated and innate intestinal inflammation
[51]. In line with these results, Helicobacter pylori-colon-
ised patients who developed peptic ulcer disease displayed
reduced Treg function compared with patients without pep-
tic ulcer disease, suggesting a tissue protective role for
Tregs also in human settings [52].
While insufficient suppression by Tregs can favour tissue
damage, an imbalance in effector versus regulatory re-
sponse in favour of inhibitory Treg function can promote
pathogen persistence. Consequently, enhanced Treg func-
tion or numbers have been linked to poor effector T cell
function and pathogen clearance in a number of chronic in-
fections in mice and humans. During retroviral infection
of mice inhibition of Treg function by anti-glucocorticoid-
induced tumour necrosis factor receptor (anti-GITR) treat-
ment can improve CD8+ T cell function and reduce viral
load [53]. This indicates that suppression by Tregs hampers
CD8+ T cell responses and thereby promotes viral per-
sistence. In patients with human immunodeficiency virus
(HIV) infection, a correlation between viral load and Foxp3
expression in T cells has also been suggested [54]. In ex-
treme cases, inhibition of effector responses by Tregs can
lead to host death, as demonstrated in mice infected with
the malaria parasite Plasmodium yoelii [55]. Expansion
of Tregs and TGF-β signalling also correlates with higher
rates of parasite growth in malaria patients, pointing to-
wards a similar role of Tregs in promoting parasite persist-
ence in humans [56].
Tregs have repeatedly been linked to T cell exhaustion,
which is commonly observed in chronic infections and
characterised by reduced effector function and high ex-
pression of inhibitory receptors [57]. This is, for instance,
the case in mice chronically infected with lymphocytic
choriomeningitis virus (LCMV), where Treg depletion and
blockade of the programmed death 1 / programmed death
ligand 1 (PD-1/PD-L1) pathway results in recovery of
CD8+ T cell effector functions and the reduction of viral
titres [58]. Treg-mediated immune suppression may repres-
ent a general mechanism for immune evasion during es-
tablishment of chronic viral infection [59]. How this can
be achieved in an immunological sense is still largely un-
known [57]. One possible antagonist of exhaustion is the
proinflammatory cytokine IL-21, as absence of IL-21 sig-
nalling leads to expansion of Tregs and promotes CD8+ T
cell exhaustion during chronic LCMV infection [60]. In the
latter study it was also demonstrated that depletion of Tregs
during chronic viral infection can lead to lethal immuno-
pathology, highlighting again the importance of an equilib-
rium between inhibitory and effector immune mechanisms.
Many studies focused on Tregs during chronic infections,
but their role in acute infections seemed to be minor and
has so far been subject of only a few studies [5]. However,
recent reports show that the involvement of Tregs in im-
mune responses during acute infections might indeed be
more complex than initially thought. Although depletion
of Tregs has no significant effect on the course of primary
influenza infection in mice [61], another study observed
the emergence of antigen-specific Tregs that persisted after
acute infection and were tissue protective in a homologous
challenge [62]. Furthermore, through their secretion of am-
phiregulin in response to the alarmins IL-33 and IL-18,
Tregs play a direct role in tissue protection and repair
[63–65]. These observations showcase the diverse func-
tions of Tregs during acute infections, and illustrate that
their role in this setting is still only poorly understood and
probably depends on various factors, including the patho-
gen itself as well as the site of infection.
Regulatory T cells in cancer
Immune surveillance is essential for eradication of aberrant
cells and prevention of their progression to cancer. Based
on their regulatory function, an involvement of Tregs in
tumour progression was long suspected [66]. In some hu-
man cancers, high prevalence of Tregs and low numbers of
CD8+ effector T cells are associated with poor prognosis
(reviewed in [6]). To date there is still relatively little
known about the function and plasticity of tumour-associ-
ated Tregs. Nevertheless, Tregs are thought to inhibit po-
tent anti-tumour responses under certain conditions and
many approaches to the development of cancer immuno-
therapies focused on the induction of anti-tumour immu-
nity by reducing the suppressive capacity of Tregs.
A now widely utilised cancer immunotherapy is high-dose
IL-2. This has been successfully applied for treatment of
metastatic melanoma and renal cell carcinoma [67, 68].
Since IL-2 can promote effector T cell differentiation and
stimulate natural killer (NK) cells, the prolonged survival
in treated patients may be attributed to increased anti-tu-
mour immune responses [69]. A drawback of this treatment
lies in the high doses of IL-2 required, which can lead
to serious side effects [69]. However, high doses seem to
be necessary for the induction of anti-tumour immune re-
sponses, as low doses preferentially expand Tregs owing
to their expression of the high-affinity IL-2 receptor, which
includes the IL-2 receptor α-chain (CD25) [47]. In contrast,
effector T cells are mostly restricted to expressing the low-
affinity IL-2 receptor and thus require higher concentra-
tions of IL-2 for activation (fig. 1C). The differential ex-
pression of high versus low affinity IL-2 receptors in ef-
fector T cells and Tregs might, under certain circum-
stances, even interfere with the responsiveness of patients
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to high-dose IL-2 treatment. For instance, one study repor-
ted the expansion of an activated Treg subset in melanoma
patients treated with high-dose IL-2 [70]. This study also
came to the conclusion that more prominent expansion of
this Treg subset predicted poorer responsiveness towards
high-dose IL-2 therapy. To counteract these unwanted ef-
fects, it may be beneficial to combine IL-2 treatment with
depletion or inhibition of Tregs. This could potentially in-
crease the efficacy of IL-2 in triggering an anti-tumour re-
sponse and hence might even allow for administration of
less toxic IL-2 dosages. The principle of Treg depletion as a
possible cancer treatment was already explored over a dec-
ade ago, and was shown to slow tumour growth and en-
hance anti-tumour immunity [71, 72]. However, when con-
sidering Treg depletion via the CD25-blocking antibody
daclizumab, it is important to note that CD25 is also ex-
pressed on activated effector T cells and, depending on the
timing and dose, daclizumab might also deplete effector
T cells. Furthermore, Treg depletion generally harbours
the risk of causing autoimmunity. Selective stimulation of
specific lymphocyte subsets by use of IL-2-antibody com-
plexes has also been suggested as an alternative to classic
IL-2 immunotherapy in order to minimise its shortcomings
[69]. Depending on the antibody clone, IL-2-antibody com-
plexes direct activity of IL-2 towards CD25+ cells such
as Tregs or selectively expand CD122high effector cells in
mice [73, 74]. Therefore, the use of IL-2-antibody com-
plexes might facilitate a more tailored approach to balan-
cing the Treg / effector T cell ratio therapeutically.
Targeting of immune checkpoint inhibitors represents an-
other promising approach to activate anti-tumour immune
responses (fig. 1C). Current immunotherapies are directed
against the co-inhibitory receptors CTLA-4 and PD-1, and
exhibit unprecedented efficacy in several cancer indica-
tions [75]. Combination therapy against CTLA-4 (ipilimu-
mab) and PD-1 (nivolumab) was shown to have synergist-
ic effects in melanoma patients and significantly prolonged
progression-free survival [76]. In the mouse model, this
combined treatment resulted in increased tumour infiltra-
tion of cytotoxic T cells, reduced frequencies of Tregs
and, ultimately, tumour regression in up to 75% of mice
[77]. These results highlight the similarity between the
T cell responses in cancer and chronic infection, where
the same approach results in superior viral clearance [58].
Importantly, these co-inhibitory molecules are also highly
expressed on Tregs, where they contribute to Treg sup-
pressive function. Immune checkpoint blockade is there-
fore likely to both interfere with Treg function and enhance
effector responses, and thereby promote the effector re-
sponse through two synergistic pathways. This dual action
of checkpoint inhibitors was investigated in detail in a
recent set of studies on the novel co-inhibitory receptor
TIGIT (T cell immunoglobulin and immunoreceptor
tyrosine-based inhibition motif [ITIM] domain), which re-
cently gained attention as another potential checkpoint in-
hibitor for cancer therapy. Like CTLA-4 and PD-1, TIGIT
is expressed on effector as well as regulatory T cells, and
mechanistic studies in mice revealed that anti-TIGIT ther-
apy affects both CD8+ T cell responses as well as Tregs,
supporting an impact of checkpoint inhibitors on both ef-
fector as well as regulatory T cell function [78–80].
As illustrated by both IL-2 treatment and the checkpoint in-
hibitor approaches, a key aspect in effective cancer immun-
otherapies lies in skewing the balance of Tregs and effector
T cells towards an increased effector response. A better un-
derstanding of the dynamics of marker expression on both
effector and regulatory T cells in the different disease set-
tings, as well as a detailed assessment of their expression
patterns in patients will be an important step to improve
therapeutic efficacy and minimise side effects.
Conclusions
The studies discussed here emphasise the broad impact
Tregs have on the development of tolerance versus immu-
nity. Consequently their manipulation harbours enormous
therapeutic potential for the treatment of a wide spectrum
of diseases ranging from autoimmunity to chronic infec-
tion and cancer. However, in order to realise this poten-
tial, a better understanding of the underlying Treg biology
is essential. In particular, deeper insight into the mechan-
isms that govern Treg stability, plasticity, and specialisation
will be necessary to allow tailored manipulation of Treg
numbers and function aimed at re-establishing a healthy
balance between tolerance and protective immunity in this
broad range of diseases.
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Figure 1
Therapeutic targeting of the effector T cell–Treg balance. Depicted are approaches that can restore a dysfunctional ratio of effector T cells
and Tregs in different diseases to the healthy state (A). (B) In autoimmune diseases, self-tolerance is lost and autoreactive effector T cells
expand. In Th17-driven autoimmune diseases, blocking of IL-6 signalling favours Treg and inhibits Th17 differentiation. Low-dose IL-2 therapy,
which leads to expansion of Tregs and thus restores a healthy effector T cell–Treg balance represents a more general approach for treatment of
autoimmunity. (C) Application of high-dose IL-2 results in expansion of effector T cells and induction of antitumor immune responses in cancer
patients. Checkpoint inhibitors block signalling through inhibitory receptors such as PD-1 or CTLA-4 and can thus reverse T cell exhaustion,
which favours immune evasion of tumour cells or pathogens. Blockade of these pathways can additionally support the function of effector T cells
by reducing the suppressive capacity of Tregs.
CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; IL = interleukin; PD-1 = programmed death 1; Th = T helper cell; Treg = regulatory T cell
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